A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
第一作者:
Jean-Louis,Pujol
第一单位:
Department of Thoracic Oncology, Montpellier Regional University Hospital, Montpellier, France. Electronic address: jl-pujol@chu-montpellier.fr.
作者:
主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);女(雌)性(Female);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);小细胞肺癌(Small Cell Lung Carcinoma)
DOI
10.1016/j.jtho.2019.01.008
PMID
30664989
发布时间
2020-06-30
- 浏览17

Journal of thoracic oncology
903-913页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文